NAMS
NewAmsterdam Pharma Company N.V.Data as of 2026 Q2 (06-30) · 13F snapshot
Summary
NewAmsterdam Pharma Company N.V. (NAMS) is held as common stock by 6 tracked hedge-fund managers, with a combined reported value of ~$293.81M; the largest are Andreas Halvorsen, Stanley Druckenmiller, Ken Griffin. 2 tracked managers also disclosed PUT or CALL positions, reported separately below. This quarter: 2 new, 1 added, 1 trimmed. Data as of 2026 Q2, from public SEC 13F filings, delayed up to ~45 days.
Attention · MediumThis quarter · Heating up
Common-stock holders62 also report options
Congress trades0
Price$23.81vs quarter-end-29.74%
Sectors0
This quarter's moves
Top holderNew2
Added1
Trimmed / sold1
Andreas HalvorsenCommon-stock positions
PUT and CALL disclosures are excluded from these holder counts and values.
Value $142.46M0.4% of portfolio4,203,5672026 Q2
Value $104.05M2.4% of portfolio3,070,1462026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Andreas Halvorsen | $142.46M | 0.4% | Hold |
| Stanley Druckenmiller | $104.05M | 2.4% | Hold |
PUT / CALL disclosures
Reported separately: 13F option values are not common-stock ownership and do not reveal the full strategy or economic exposure.
Value $1.30M— of portfolio38,4002026 Q2
Value $620.2K— of portfolio18,3002026 Q2
Value $620.2K— of portfolio18,3002026 Q2
| Investor | Value | % of portfolio | Action |
|---|---|---|---|
| Ken GriffinCALL | $1.30M | — | — |
| Steven CohenCALL | $620.2K | — | — |
| Steven CohenPUT | $620.2K | — | — |
Public SEC 13F filings may appear up to 45 days after quarter-end; STOCK Act / OGE trade filings are generally due within 45 days but may be late. Partial data only — research, not investment advice.